
1. top antivir med. 2016 may-jun;24(1):59-81.

croi 2016: advances antiretroviral therapy.

taylor bs(1), olender sa(2), tieu hv(3), wilkin tj(4).

author information: 
(1)university texas health science center, san antonia, tx, usa.
(2)columbia university medical center, new york, ny, usa.
(3)columbia university medical center new york blood center, new york, ny,
usa.
(4)weill cornell medicine, new york, ny, usa.

the 2016 conference retroviruses opportunistic infections highlighted
exciting advances antiretroviral therapy, including important data on
investigational antiretroviral drugs clinical trials. clinical trials
demonstrated benefits long-acting injectable coformulation given as
maintenance therapy, examined intravenous subcutaneous administration a
monoclonal antibody directed cd4 binding site hiv-1, provided novel
data tenofovir alafenamide. several studies focused role hiv drug
resistance, including significance minority variants, transmitted drug
resistance, use resistance testing, drug class-related resistance. novel
data hiv care continuum low- middle-income settings concentrated on
differentiated hiv care delivery models outcomes. data progress toward
reaching world health organization 90-90-90 targets well outcomes related
to expedited initiation hiv treatment adherence strategies presented.
results trial malawi showed reduced rates mother-to-child
transmission among hiv-infected women initiated antiretroviral therapy prior 
to pregnancy, several studies highlighted effect antiretroviral
therapy pediatric populations. special session dedicated findings
of studies ebola virus disease treatment outbreak west
africa.


pmcid: pmc6148924
pmid: 27398863  [indexed medline]

